NCT00077675View on ClinicalTrials.gov

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

PHASE2CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions
Infections, Gram-positive Bacterial
Interventions
DRUG

Telavancin

Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days

DRUG

vancomycin or antistaphylococcal penicillin

Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.

Trial Locations (1)

91950

Paradise Valley Hospital, 2400 E. 4th Street, National City

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY

NCT00077675 - Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) | Biotech Hunter | Biotech Hunter